A variety of oral and systemic medicines can have a harmful effect on the eyes.1 Some of the adverse effects may be dose-related, while others may not be.

Patients may not be aware of the relationship between the medication and their eye condition, and may not think to mention this to you, unless you specifically ask what medicines they are currently taking. They may not remember the name of their condition or the names of the medicine.

It is therefore helpful to be familiar with the different adverse effects of oral or systemic medications, so you can better identify and manage the eye condition the patient presents with. In addition to reporting the adverse reaction via the usual channels, it is advisable to contact the clinician who prescribed the medication so they can consider alternatives.

**Reporting of adverse drug reactions**

There are national adverse drug reporting centres in 153 countries worldwide. Reporting of adverse reactions is mostly voluntary, and is done by health care professionals. At the global level, the World Health Organization Programme for International Drug Monitoring collates the reports from the national centres to ensure timely identification of suspected safety problems. To find out more, including how to set up an adverse drug reporting centre in your country, visit [https://bit.ly/DrugWHO](https://bit.ly/DrugWHO).

In addition to eye care professionals, physicians prescribing these drugs must also be made aware of any potential adverse reactions. That would enable them to warn the patients to report early symptoms and to undergo regular eye check-ups wherever indicated. A list of medications which can cause ocular toxicity is given in Table 1.

**Sight-threatening adverse reactions**

**Raised intraocular pressure**

Patients may present with raised pressures in the eye caused by the intake of the following drugs.

- **Corticosteroids** (such as prednisolone or dexamethasone)2 are used as long-term medications for some joint disorders, skin diseases, auto-immune disorders and in transplant patients. They are administered by various routes: topically, orally, intravenous, nasally or as injections in joints and can raise intraocular pressure, resulting in secondary glaucoma.

- **Antihistamines, beta blockers, antidepressants, antipsychotics and some diuretics** can cause angle-closure glaucoma in pre-disposed patients who have shallow anterior chambers. These are drugs with anti-cholinergic effects and are used to treat conditions like urinary incontinence, chronic obstructive pulmonary disorder, allergies, or mental health conditions. This group of medications generally causes pupillary dilation leading to angle closure. Some sulfa-based drugs are also known to cause a similar reaction.3

- **Topiramate**, which is used to treat epilepsy, can cause uveal effusion with very high intraocular pressure.

**Figure 1** Bilateral toxic optic neuropathy with disc oedema in a 32-year-old female patient with a history of ethambutol intake and on tacrolimus after a renal transplant.
pressure. The symptoms include blurred vision, difficulty seeing, and eye pain, and usually happen in the first month of taking the medication.

Patients on these drugs must be monitored for intraocular pressure (IOP) and AC depth. Some patients are ‘high responders’ and can have significantly increased IOP. In case, corticosteroids cannot be tapered or replaced, IOP must be controlled medically.

**Cataract**
- **Corticosteroids.** Long-term use of corticosteroids can also lead to posterior sub-capsular cataract. This form of cataract leads to vision-related issues early in its course and may warrant early surgery.
- Some other less-used drugs known to cause cataracts include phenothiazines, used for behavioural disorders and busulfan, an antineoplastic drug.3

**Toxic optic neuropathy**
Patients with toxic optic neuropathy may present with bilateral, painless loss of vision (Figure 1). This has been reported with various drugs:
- Ethambutol and isoniazid, which are commonly prescribed for tuberculosis in countries where tuberculosis is endemic; the risk of toxic optic neuropathy is greater in patients who also have renal disease
- Ciprofloxacin and chloramphenicol, both antimicrobial medications
- Antimetabolite medicines used in the treatment of malignancies
- Amiodarone used for arrhythmias
- Amoebicidal medications

Patients on these drugs must be screened for visual acuity, colour vision, and central vision testing. The majority of these defects can be reversed with timely discontinuation and thus, timely monitoring is essential.

**Retinal haemorrhages and internal ocular bleeding**
Bleeding in retinal tissues can lead to sight loss. This may be caused by the following medication:
- Anticoagulants used for the prevention of heart disease and stroke
- Antineoplastic drugs used for malignancies.

This can be monitored using blood tests and medication may need to be discontinued in some cases, especially where a minor bleed has already occurred. These drugs can also lead to bleeding during eye surgery and may have to be discontinued prior to some eye surgeries. It is therefore vital that eye surgeons know about patients’ usage of such drugs.

**Retinal toxicity**
Some drugs can cause damage to one of the layers of the retina (retinal pigment epithelial loss). Unfortunately, some of these patients may already have central visual loss when they present. Retinal toxicity is irreversible, thus early recognition by regular screening, and early discontinuation, is imperative.
- **Chloroquine and hydroxychloroquine** are antimalarial drugs. They are more likely to cause retinal toxicity when used for longer periods of time, either to treat other inflammatory conditions of the joints or – more recently – as prophylaxes for COVID-19.
- Thioridazine and chlorpromazine are phenothiazines used for the treatment of anxiety, depression, and other behavioural disorders.

Check patients’ vision using manual or automated visual field testing or spectral-domain optical coherence tomography (if available). Multifocal electoretinogram (mFERG), if available, can be used for objective corroboration with visual fields.

**Other potentially sight-threatening adverse reactions to medication**
- **Central serous retinopathy.** Corticosteroids can cause central serous retinopathy (CSR) in some patients.
- **Intracranial hypertension.** Tetracycline, which is used long-term for conditions like rosacea can lead to intracranial hypertension or pseudotumor cerebri, which may lead to optic atrophy if left untreated.
- **Stevens-Johnson syndrome.** This is a relatively rare drug reaction, characterised by skin and mucosal involvement. It has an acute phase with severe pseudomembranous conjunctivitis (Figure 2) and a chronic phase with extreme dry eye and cicatricial features (Figure 3) and can be caused by common drugs such as painkillers or cold and flu medication. Over one hundred drugs have been associated with this syndrome.7 In the acute phase, treatment includes management of pain, topical and systemic anti-inflammatory medications, and antibiotics to control infection.
Non-sight-threatening adverse reactions

These side effects may cause discomfort but may not be directly sight threatening.

**Corneal vortex keratopathy**

This is a whorl-like pattern on the cornea and is generally not visually significant. These are mostly caused by amiodarone, a drug used to treat cardiac arrhythmia. Some of the other drugs which can cause this are chloroquine, hydroxychloroquine, indomethacin, and tamoxifen. The dosages need to be reduced only if the corneal condition causes extreme discomfort or blurring of vision.

**Floppy iris syndrome**

Another specific drug-induced condition is one in which there is an effect on the constrictor muscles of the iris, leading to poor dilation and floppy iris during cataract surgery. This is generally caused by alpha-1 blockers like tamsulosin (used for prostatic hypertrophy). These technical issues during cataract surgery can be prevented if adequate precautions are taken, so patient’s usage of these drugs must be known to the surgeon. It is sometimes recommended that tamsulosin be stopped two weeks before surgery, but it may be more important that the surgeon is made aware that the patient is taking one of these drugs.

**Dry eye**

A diverse group of orally administered medications have been linked with dry eye. These include antihypertensive drugs such as atenolol and acebutolol, antihistamines such as cetirizine, antivirals such as aciclovir, analgesics (e.g., ibuprofen) and some antidepressants, antipsychotic, and anti-arrhythmic medications (see Table 1). Other conditions, like epiphora, blepharitis, and conjunctivitis can also be side effects of some anti-malignancy drugs that are administered systematically.

---

**Table 1 Drugs that can cause ocular toxicity.**

<table>
<thead>
<tr>
<th>Oral drugs</th>
<th>Use</th>
<th>Possible ocular side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topiramate</td>
<td>Treatment of epilepsy</td>
<td>Secondary angle-closure glaucoma, visual field defects, oculargyric crisis, uveitis</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>Treatment of epilepsy</td>
<td>Nystagmus, diplopia and visual field defects</td>
</tr>
<tr>
<td>Vigabatrin</td>
<td>Treatment of epilepsy</td>
<td>Visual field constriction, optic nerve atrophy</td>
</tr>
<tr>
<td>Bisphosphonates (e.g., alendronate sodium, risendronate, zoledronic acid)</td>
<td>Treatment and prevention of osteoporosis</td>
<td>Inflammation in the eye leads to conjunctivitis, episcleritis, scleritis, keratitis or uveitis, or corneal and scleral melting</td>
</tr>
<tr>
<td>Chloroquine-based drugs (chloroquine, hydroxychloroquine)</td>
<td>Treatment of malaria</td>
<td>Maculopathy, peripheral retinopathy</td>
</tr>
<tr>
<td>Corticosteroids (e.g., prednisolone, dexamethasone)</td>
<td>Anti-inflammatory</td>
<td>Corticosteroid-induced raised intraocular pressure can lead to glaucoma, acceleration of cataract progression, and subcapsular cataracts.</td>
</tr>
<tr>
<td>Ethambutol</td>
<td>Treatment of tuberculosis</td>
<td>Optic neuropathy characterised by bilateral central visual loss, decreased colour vision, central visual field defects, and (eventually) optic atrophy</td>
</tr>
<tr>
<td>Fingolimod</td>
<td>Treatment of multiple sclerosis</td>
<td>Macular oedema, blurred vision, distortion, and impaired reading vision</td>
</tr>
<tr>
<td>Isotretinoin and vitamin A</td>
<td>Acne and Vitamin A deficiency treatment, respectively</td>
<td>Blepharoconjunctivitis, chalazia, corneal opacities, dry eyes, retinopathy</td>
</tr>
<tr>
<td>Mitogen-activated protein kinase kinase enzyme (MEK) inhibitors, e.g., crizotinib</td>
<td>Treatment of advanced non-small cell lung cancer</td>
<td>Decreased visual acuity, visual field defects, dry eye symptoms, eyelid abnormalities, retinal vein occlusion, and retinopathy</td>
</tr>
<tr>
<td>Pentosan polysulfate</td>
<td>Relief of bladder pain and discomfort related to interstitial cystitis</td>
<td>Maculopathy, retinal pigment epithelial lesions</td>
</tr>
<tr>
<td>Phenothiazines</td>
<td>Treatment of schizophrenia and other psychotic disorders</td>
<td>Abnormal pigmentation of the eyelids, conjunctiva and cornea. Corneal epithelial changes (high dose). Corneal oedema (rare).</td>
</tr>
<tr>
<td>Phosphodiesterase type 5 inhibitors, e.g., sildenafil, tadalafil</td>
<td>Treatment of erectile dysfunction</td>
<td>Persistent blurred vision, non-arteritic ischaemic optic neuropathy, cilioretinal artery occlusion, or central serous chorioretinopathy.</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>Treatment of breast cancer</td>
<td>Intraretinal crystalline deposits, macular oedema, and punctate retinal pigmentary changes.</td>
</tr>
<tr>
<td>Tetracyclines, e.g., doxycycline, tetracycline</td>
<td>Antibiotics</td>
<td>Nausea, vomiting, and morning headaches may be symptoms of idiopathic intracranial hypertension which can lead to permanent loss of vision</td>
</tr>
<tr>
<td>Thiazolidinediones, e.g., glitazones, pioglitazone, rosiglitazone</td>
<td>Management of type 2 diabetes mellitus</td>
<td>Macular oedema</td>
</tr>
</tbody>
</table>

---

**References**